

NeuTec Pharma plc

14 October 2003

***NeuTec* announces changes to the Board**

14 October 2003 – Manchester, UK: *NeuTec* Pharma plc, the biopharmaceutical company targeting drug-resistant life-threatening infections, today announces the appointment of Dr Robert Nolan as a Non-Executive with immediate effect.

Dr Nolan has over 30 years of experience in the pharmaceutical industry and has been Director of Global Licensing at AstraZeneca since 1989. He currently manages major product licensing transactions world-wide, ranging from several million dollars to \$120million. The partnering companies are both virtual biotech start-ups as well as multi-billion dollar entities.

As Director of Global Licensing, Dr Nolan's high profile role encompasses many therapeutic areas, including central nervous system and cardiovascular. However, more recently he has been focusing on licensing deals in cancer and infection, as well as in and out licensing various technologies.

Prior to his current role, Dr Nolan spent ten years at ICI Pharmaceuticals, working in Natural Products Research, seeking novel anti-bacterial and anti-cancer agents. Earlier in his career he was laboratory head of biochemistry and protein synthesis for Sandoz Forschungsinstitut in Vienna.

Rodney Graves, Non-Executive of *NeuTec*, will not be seeking reappointment to the Board at the forthcoming Annual General Meeting.

Professor James Burnie, Chief Executive Officer of *NeuTec* Pharma, said: *"We are pleased to welcome such a high profile candidate as Robert to the Board and believe his strong commercial experience will contribute greatly to the Company. I would also like to thank Rodney for his contribution to the company over the years."*

There are no disclosures required under paragraph 6.F.2 (b)-(g) of the Listing Rules of the U.K.L.A.

For further details please contact:

NeuTec Pharma plc

Andrew King, Finance Director

07771 867890

Financial Dynamics

Ben Atwell / Lucy Briggs

020 7831 3113

Notes to editors:

NeuTec Pharma plc is a biopharmaceutical company formed in 1997 which specialises in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. In February 2002 the Company’s equity was admitted on the Alternative Investment Market (“AIM”) of the London Stock Exchange.

The development of NeuTec's products differs from the traditional approach used by conventional pharmaceutical companies which screen numerous chemical compounds for activity against bacteria and fungi. Many of these compounds will be too toxic for human use. In contrast, NeuTec identifies naturally occurring potentially protective antibodies from patients who have recovered from bacterial and fungal infections and then uses these to generate “grabs” to treat these infections. As a result, these “grabs” are likely to be intrinsically safer than antibiotics.

NeuTec's two leading drug candidates are Mycograb®, which targets systemic candidiasis, and Aurograb®, which targets Staphylococcus aureus including methicillin-resistant Staphylococcus aureus (“MRSA”).

NeuTec uses its platform technology Fabtec® for the identification of new therapeutic antibody fragments. This technology is available for licensing.